Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD33/CLL1 CAR-NK Cells in AML
NCT05215015Phase 1Unknown
- Sponsor
- Wuxi People's Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD33/CLL1 CAR-NK cells in acute myeloid leukemia (AML), sponsored by Wuxi People's Hospital. Primary endpoint: Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
anti-CD33/CLL1 CAR-NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05215015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215015.